From the Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh.
Department of Medical Oncology, Fortis Hospital, Ludhiana, Punjab, India.
Clin Nucl Med. 2023 Oct 1;48(10):e470-e471. doi: 10.1097/RLU.0000000000004781. Epub 2023 Aug 3.
177 Lu-PSMA radioligand therapy (RLT) has shown very encouraging results in metastatic castrate-resistant prostate cancer (mCRPC) patients with acceptable adverse events. The adverse events of RLT are mainly limited to salivary glands and kidneys. However, there is dearth of available data of RLT in transplanted kidney patients with mCRPC. Here is a case of 68-year-old mCRPC patient with history of renal transplant who underwent 4 cycles of 177 Lu-PSMA-617 RLT (~7.4 GBq/cycle). Posttherapy serum creatinine and glomerular filtration rate remained stable along with excellent response and symptomatic improvement, thus demonstrating the safety of full dose of 177 Lu-PSMA in renal transplant patients.
177Lu-PSMA 放射性配体治疗（RLT）在转移性去势抵抗性前列腺癌（mCRPC）患者中显示出非常令人鼓舞的结果，且不良反应可接受。RLT 的不良反应主要局限于唾液腺和肾脏。然而，mCRPC 移植肾患者的 RLT 可用数据稀缺。本文报告了一例 68 岁 mCRPC 患者，既往有肾移植病史，接受了 4 个周期的 177Lu-PSMA-617 RLT（~7.4GBq/周期）。治疗后血清肌酐和肾小球滤过率保持稳定，同时疗效和症状均得到改善，表明在移植肾患者中使用全剂量 177Lu-PSMA 是安全的。
